This
time it is Nexavar (Sorafenib)
A cancer treatment from Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals Inc. failed to meet its main, late-stage study goal of improving overall survival in patients with advanced cases of lung cancer
From wiki:
Sorafenib (a bi-aryl urea[2]) is a small
molecular inhibitor of several Tyrosine protein kinases (VEGFR and PDGFR) and
Raf kinases (more avidly C-Raf than B-Raf).
(Protein kinases are overactive in many of
the molecular pathways that cause cells to become cancerous. These pathways
include Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 and
3 kinases and c Kit the receptor for Stem cell factor. )
Sorafenib is/was unique in targeting the
Raf/Mek/Erk pathway (MAP Kinase pathway).
Sorafenib inhibits some intracellular
serine/threonine kinases (e.g. C-Raf, wild-type B-Raf and mutant B-Raf).
Well, I
have already written about inefficiency of the
“targeted
approach” as well as about the cost
of such
approach! Who will fail next?
No comments:
Post a Comment